About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingPhase 1NCT07367958

A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects

This is phase 1 study to Compare the Pharmacokinetics, Safety and Immunogenicity of the Auto-injector and Pre-filled syringe of CT-P52 in Healthy Male Subjects.

Lead sponsor: Celltrion•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Celltrion

CT-P52, containing the active ingredient ixekizumab, is being developed by CELLTRION, Inc. as a proposed biosimilar to the reference product, Taltz. In this study, Pharmacokinetics, Safety and Immunogenicity of the Auto-injector and Pre-filled syringe of CT-P52 will be evaluated in Healthy Male Subjects.

Age

19 - 55 years

Sex

MALE

Healthy Volunteers

Yes

Inclusion Criteria

•Healthy male subjects, between the ages of 19 and 55 years, both inclusive.
•Subject has a body weight between 60 to 90 kg, both inclusive, and a BMI between 18.0 and 29.9 kg/m2, both inclusive, when rounded to the nearest tenth.

Exclusion Criteria

•A medical history and/or condition that is considered significant
•Clinically significant allergic reactions, hypersensitivity
•History or current infection of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, or syphilis
•Active or latent Tuberculosis
•History of malignancy
•Previous exposure to ixekizumab or a biosimilar of ixekizumab or any drug that directly targets Interleukin (IL)-17 or the IL-17 receptor

Related studies

COMPLETEDPhase 1

Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers

NCT05245669 · Healthy Male Subjects

COMPLETEDPhase 1

A Human AME Study for Omaveloxolone

NCT03931590 · Healthy Male Subjects

COMPLETEDPhase 1

Mass Balance Study of TS-142 in Healthy Adult Subjects.

NCT04814771 · Healthy Male Subjects

COMPLETEDPhase 1/2

A Study of PET/CT Imaging Using INR101 Injection in Healthy Male Subjects and Patients With Suspected Prostate Cancer

NCT06472531 · Healthy Male Subjects, Suspected Prostate Cancer

COMPLETEDPhase 1

Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects

NCT06111196 · Healthy Male Subjects

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 13, 2026Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhasePHASE1

Enrollment218

Start dateJan 2026

Last updatedApr 13, 2026

Condition

Healthy Male Subjects

Locations shown

Korea University Guro Hospital

Seoul, Seoul (Seoul Special City)

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 13, 2026Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions